Business, energy, technology, markets and global industry news from Business News Today

MaaT013

PharmaDeviceNews MaaT013
Pharma & Biotech

MaaT Pharma AGM strengthens funding authority as MaaT013 faces September regulatory test

MaaT Pharma shareholders have preserved the biotechnology firm’s ability to raise capital as MaaT013 enters a decisive regulatory re-examination and its operating cash runway narrows.

Read More
A clinician reviews an investigational treatment as MaaT Pharma prepares to challenge the negative European regulatory opinion on MaaT013 for acute graft-versus-host disease. Representative image.
Pharma & Biotech

MaaT Pharma seeks second review of MaaT013 as regulators question single-arm evidence

Discover why MaaT Pharma is challenging the negative CHMP opinion on MaaT013 and what the September review means for acute graft-versus-host disease.

Read More
Representative image of microbiome-based therapy research as MaaT Pharma advances MaaT013 after pivotal Phase 3 GI-aGvHD data, highlighting the growing regulatory and clinical focus on microbiome therapeutics in transplant medicine.
Pharma & Biotech

Why MaaT Pharma’s MaaT013 survival signal could reshape refractory GI-aGvHD treatment debate

MaaT Pharma’s MaaT013 posted pivotal Phase 3 GI-aGvHD data. Read what it could mean for EMA approval, adoption, and microbiome therapeutics.

Read More